Therefore, improving the PARPi-mediated STING activation and subsequent type I interferon (IFN-I) expression may lead to enhanced immunogenicity of PARP inhibitors in breast cancer, improving overall efficacy11,12. This evidence concerns the gene PARP1 and breast cancer.